Journal
ARCHIVES OF PHARMACAL RESEARCH
Volume 37, Issue 4, Pages 435-439Publisher
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-013-0283-3
Keywords
GPR40 agonist; Antidiabetics; Type 2 diabetes mellitus
Categories
Funding
- Hanyang University [HY-2012-00000002365]
Ask authors/readers for more resources
With growing needs for new antidiabetic drugs which are safe and effective alone or in combination with existing drugs, G-protein coupled receptor 40 (GPR40) has drawn a considerable attention as a potential therapeutic target for type 2 diabetes. As GPR40 agonist may offer advantages to commonly used agents, by acting ambient glucose dependent manner which mechanistically leads to reduced risk of developing hypoglycemia. Since deorphanization in 2003, development of small molecule GPR40 agonists has been spurred by several research groups. There are a number of lead molecules targeting GPR40, and among these molecules TAK-875 (full agonist) and AMG 837 (partial agonist) advanced into clinical stage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available